Citation Impact
Citing Papers
Endotoxemia and sepsis mortality reduction by non-anticoagulant–activated protein C
2007
Comparison of Two Fluid-Management Strategies in Acute Lung Injury
2006 Standout
Trained immunity: A program of innate immune memory in health and disease
2016 StandoutScience
Empiric Combination Antibiotic Therapy Is Associated with Improved Outcome against Sepsis Due to Gram-Negative Bacteria: a Retrospective Analysis
2010
Intensive versus Conventional Glucose Control in Critically Ill Patients
2009 Standout
The NICE-SUGAR (Normoglycaemia in Intensive Care Evaluation and Survival Using Glucose Algorithm Regulation) Study: statistical analysis plan
2009
Efficacy of Therapy with Recombinant Human Activated Protein C of Critically Ill Surgical Patients with Infection Complicated by Septic Shock and Multiple Organ Dysfunction Syndrome
2011
Safety of Drotrecogin Alfa (Activated) in Surgical Patients with Severe Sepsis
2004
Protein C concentrations in severe sepsis: an early directional change in plasma levels predicts outcome
2006
Unplanned Extubations in the Adult Intensive Care Unit
1998
Design, conduct, analysis and reporting of a multi-national placebo-controlled trial of activated protein C for persistent septic shock
2008
Satb1 regulates the effector program of encephalitogenic tissue Th17 cells in chronic inflammation
2019 StandoutNobel
Antimicrobial therapy for patients with severe sepsis and septic shock: An evidence-based review
2004
Dexmedetomidine vs Midazolam for Sedation of Critically Ill Patients<subtitle>A Randomized Trial</subtitle>
2009 Standout
Prognosis and Outcomes of Patients With Community-Acquired Pneumonia
1996
Does combination antimicrobial therapy reduce mortality in Gram-negative bacteraemia? A meta-analysis
2004
Acute kidney injury and chronic kidney disease: an integrated clinical syndrome
2012
Immunomodulation in the critically ill
2009
Anti-tumor necrosis factor therapy in sepsis: Update on clinical trials and lessons learned
2001
Sepsis after major visceral surgery is associated with sustained and interferon-γ–resistant defects of monocyte cytokine production
2000
Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study
2020 Standout
Early Goal-Directed Therapy in the Treatment of Severe Sepsis and Septic Shock
2001 Standout
Acute Kidney Injury in Older Adults
2011
Infectious Diseases Society of America/American Thoracic Society Consensus Guidelines on the Management of Community-Acquired Pneumonia in Adults
2007 Standout
Introduction of sedative, analgesic, and neuromuscular blocking agent guidelines in a medical intensive care unit: Physician and nurse adherence
2000
Cholinergic agonists inhibit HMGB1 release and improve survival in experimental sepsis
2004 Standout
Hantavirus pulmonary syndrome
2011
Nucleotide signalling during inflammation
2014 StandoutNature
Is Methicillin Resistance Associated with a Worse Prognosis in Staphylococcus aureus Ventilator-Associated Pneumonia?
2005
Acute Kidney Injury and Chronic Kidney Disease as Interconnected Syndromes
2014 Standout
Predicting Death in Patients Hospitalized for Community-acquired Pneumonia
1991
The Acute Respiratory Distress Syndrome
2000 Standout
Has Mortality from Acute Respiratory Distress Syndrome Decreased over Time?
2008
Drotrecogin Alfa (Activated) in Adults with Septic Shock
2012 Standout
Factors Associated with the Outcome of Life-Threatening Necrotizing Pneumonia due to Community-Acquired <i>Staphylococcus aureus</i> in Adult and Adolescent Patients
2010
Health Care-Associated Pneumonia (HCAP)
2011
Before–after study of a standardized hospital order set for the management of septic shock*
2006
Long-term sequelae of acute kidney injury in the ICU
2012
New Antithrombotic Drugs
2012
Host–pathogen interactions in sepsis
2007
A Prediction Rule to Identify Low-Risk Patients with Community-Acquired Pneumonia
1997 Standout
Sepsis and Septic Shock: A History
2009
Outcomes following diagnosis of acute renal failure in U.S. veterans: focus on acute tubular necrosis
2009
Activated protein C (Xigris®) treatment in sepsis: a drug in trouble
2006
Inflammation and coagulation
2010
Severe Sepsis and Septic Shock
2013 Standout
Intravenous immunoglobulin for treating sepsis, severe sepsis and septic shock
2002
VIRAL HEMORRHAGIC FEVERS AND HANTAVIRUS INFECTIONS IN THE AMERICAS
1998
Daily Interruption of Sedative Infusions in Critically Ill Patients Undergoing Mechanical Ventilation
2000 Standout
Severe protein C deficiency predicts early death in severe sepsis
2004
Acute respiratory distress syndrome 40 years later: Time to revisit its definition*
2008
Nasoenteral feeding tube placement by nurses using an electromagnetic guidance system (with )
2010
Human recombinant activated protein C for severe sepsis
2012
Low-Tidal-Volume Ventilation in the Acute Respiratory Distress Syndrome
2007
BTS guidelines for the management of community acquired pneumonia in adults: update 2009
2009
The Immunopathogenesis of Sepsis in Elderly Patients
2005
Hydrocortisone Therapy for Patients with Septic Shock
2008 Standout
How Important is Methicillin-Resistant Staphylococcus aureus as a Cause of Community-Acquired Pneumonia and What is Best Antimicrobial Therapy?
2012
A randomized, double-blind, placebo-controlled trial of TAK-242 for the treatment of severe sepsis*
2010
Angiotensin-converting enzyme 2 protects from severe acute lung failure
2005 StandoutNature
Prophylactic Heparin in Patients with Severe Sepsis Treated with Drotrecogin Alfa (Activated)
2007
Long-Term Cognitive Impairment after Critical Illness
2013 Standout
Ventilator-Induced Lung Injury
2013 Standout
Genome-Scale Identification of SARS-CoV-2 and Pan-coronavirus Host Factor Networks
2020 StandoutNobel
Community-Acquired Pneumonia Requiring Admission to an Intensive Care Unit
2007
CLINICAL TRIALS FOR SEVERE SEPSIS
1999
The Pathophysiology and Treatment of Sepsis
2003 Standout
The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: Guidelines for Reporting Observational Studies
2007 Standout
Adjunctive therapy in sepsis: a critical analysis of the clinical trial programme
1999
Treatment effects of drotrecogin alfa (activated) in patients with severe sepsis with or without overt disseminated intravascular coagulation
2004
Bundled care for septic shock: An analysis of clinical trials*
2010
Phase 2 trial of eritoran tetrasodium (E5564), a Toll-like receptor 4 antagonist, in patients with severe sepsis*
2009
Current treatment of severe sepsis
2006
Infection Rate and Acute Organ Dysfunction Risk as Explanations for Racial Differences in Severe Sepsis
2010
Consensus conference definitions for sepsis, septic shock, acute lung injury, and acute respiratory distress syndrome: Time for a reevaluation
2000
The TNF and TNF Receptor Superfamilies
2001 Standout
Pragmatic management of Panton–Valentine leukocidin-associated staphylococcal diseases
2011
Accidental removal of endotracheal and nasogastric tubes and intravascular catheters
2000
Reversal of virus-induced systemic shock and respiratory failure by blockade of the lymphotoxin pathway
1999
Association between AKI and Long-Term Renal and Cardiovascular Outcomes in United States Veterans
2013
The effect of drotrecogin alfa (activated) on long-term survival after severe sepsis *
2004
The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies
2007 Standout
Linezolid in Methicillin-Resistant Staphylococcus aureus Nosocomial Pneumonia: A Randomized, Controlled Study
2012
The inflammatory reflex
2002 StandoutNature
The acute respiratory distress syndrome
2012 Standout
Incidence and Outcomes of Acute Lung Injury
2005 Standout
Prevalence and Significance of Coagulation Abnormalities in Community-Acquired Pneumonia
2009
The Epidemiology of Sepsis in the United States from 1979 through 2000
2003 Standout
The Use of Continuous IV Sedation Is Associated With Prolongation of Mechanical Ventilation
1998
Duodenal Infusion of Donor Feces for Recurrent Clostridium difficile
2013 Standout
The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions: Explanation and Elaboration
2009 Standout
Delirium in Mechanically Ventilated Patients
2001 Standout
The immunopathogenesis of sepsis
2002 StandoutNature
Effects of drotrecogin alfa (activated) on organ dysfunction in the PROWESS trial*
2003
Impacts of biodiversity on the emergence and transmission of infectious diseases
2010 StandoutNature
Neuromuscular Blockers in Early Acute Respiratory Distress Syndrome
2010 Standout
The Richmond Agitation–Sedation Scale
2002 Standout
Staphylococcus aureus Infections: Epidemiology, Pathophysiology, Clinical Manifestations, and Management
2015 Standout
Haploid Genetic Screen Reveals a Profound and Direct Dependence on Cholesterol for Hantavirus Membrane Fusion
2015
Better Reporting of Harms in Randomized Trials: An Extension of the CONSORT Statement
2004
The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3)
2016 Standout
Management of the agitated intensive care unit patient
2002
Preventing Complications of Central Venous Catheterization
2003 Standout
Acute Respiratory Distress Syndrome
2012 Standout
Ethyl pyruvate prevents lethality in mice with established lethal sepsis and systemic inflammation
2002
A2B Adenosine Receptor Blockade Enhances Macrophage-Mediated Bacterial Phagocytosis and Improves Polymicrobial Sepsis Survival in Mice
2011
Emerging Infectious Diseases of Wildlife-- Threats to Biodiversity and Human Health
2000 StandoutScience
Antipurified-Protein-Derivative Antibody in Tuberculous Pleural Effusions
1990 StandoutNobel
Delaying the Empiric Treatment of Candida Bloodstream Infection until Positive Blood Culture Results Are Obtained: a Potential Risk Factor for Hospital Mortality
2005 Standout
A Randomized Trial of Protocol-Based Care for Early Septic Shock
2014 Standout
Aspergillus fumigatusand Aspergillosis
1999 Standout
Oral Rivaroxaban for the Treatment of Symptomatic Pulmonary Embolism
2012 Standout
A Common Dominant TLR5 Stop Codon Polymorphism Abolishes Flagellin Signaling and Is Associated with Susceptibility to Legionnaires' Disease
2003 StandoutNobel
The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: Guidelines for Reporting Observational Studies
2007 Standout
Targeted adenovirus-induced expression of IL-10 decreases thymic apoptosis and improves survival in murine sepsis
2001
Flagellin, a Novel Mediator of Salmonella-Induced Epithelial Activation and Systemic Inflammation: IκBα Degradation, Induction of Nitric Oxide Synthase, Induction of Proinflammatory Mediators, and Cardiovascular Dysfunction
2001
Invited Review: Mechanisms of ventilator-induced lung injury: a perspective
2000
Therapeutic antibodies that target inflammatory cytokines in autoimmune diseases
2015
Reply to Taccone et al, Wolff and Mourvillier, Masuta and Iwata, and Lahey
2012
Part 8: Adult Advanced Cardiovascular Life Support
2010 Standout
Inhibition of the oxygen sensor PHD2 in the liver improves survival in lactic acidosis by activating the Cori cycle
2015 StandoutNobel
Sepsis: Multiple Abnormalities, Heterogeneous Responses, and Evolving Understanding
2013
PAF-mediated pulmonary edema: a new role for acid sphingomyelinase and ceramide
2004
Clinical Practice Guidelines for Sustained Neuromuscular Blockade in the Adult Critically Ill Patient
2016
Works of Howard Levy being referenced
Postpyloric Feeding Tube Placement and the Use of Electromyography Technology
1997
Drotrecogin alfa (activated) in children with severe sepsis: a multicentre phase III randomised controlled trial
2007
The value of bronchoalveolar lavage and bronchial washings in the diagnosis of invasive pulmonary aspergillosis
1992
Extended Evaluation of Recombinant Human Activated Protein C United States Trial (ENHANCE US)
2004
Cardiopulmonary manifestations of hantavirus pulmonary syndrome
1996
Severe community-acquired pneumonia as a cause of severe sepsis: Data from the PROWESS study*
2005
Recombinant platelet-activating factor acetylhydrolase to prevent acute respiratory distress syndrome and mortality in severe sepsis: Phase IIb, multicenter, randomized, placebo-controlled, clinical trial*
2003
The clinical evaluation committee in a large multicenter phase 3 trial of drotrecogin alfa (activated) in patients with severe sepsis (PROWESS): Role, methodology, and results*
2003
Hantavirus pulmonary syndrome: radiographic findings in 16 patients.
1994
Confirming the Reliability of the Sedation‐Agitation Scale Administered by ICU Nurses without Experience in Its Use
2001
A Comparative Study of Oral Endotracheal Tube Securing Methods
1993
Enzyme-Linked Immunosorbent Assay for the Detection of Antibodies Against Mycobacterium tuberculosis in Bronchial Washings and Serum
1988
Drotrecogin alfa (activated) administration across clinically important subgroups of patients with severe sepsis
2003
Liposomal prostaglandin E1 (TLC C-53) in acute respiratory distress syndrome
1999
Community-acquired pneumonia of diverse aetiology: prognostic features in patients admitted to an intensive care unit and a ?severity of illness? score
1989
Klebsiella pneumoniae bacteraemia at an urban general hospital
1990
Trace Element Homeostasis During Continuous Sedation With Propofol Containing EDTA Versus Other Sedatives in Critically Ill Patients
2000
A Multicenter, Prospective Study of the Placement of Transpyloric Feeding Tubes with Assistance of a Magnetic Device
2000
ENHANCE: Results of a global open-label trial of drotrecogin alfa (activated) in children with severe sepsis*
2006
Drotrecogin Alfa (Activated) for Adults with Severe Sepsis and a Low Risk of Death
2005
Elevated Plasma Concentrations of IL-6 and Elevated APACHE II Score Predict Acute Kidney Injury in Patients with Severe Sepsis
2006
Comparison of Bacteraemic Community-Acquired Lobar Pneumonia due to <i>Streptococcus pneumoniae</i> and <i>Klebsiella pneumoniae</i> in an Intensive Care Unit
1991
Hantavirus Pulmonary Syndrome Due to Andes Virus in Temuco, Chile
2001
Hospital mortality and resource use in subgroups of the Recombinant Human Activated Protein C Worldwide Evaluation in Severe Sepsis (PROWESS) trial *
2004
Placebo-Controlled, Double-Blind Trial of Intravenous Ribavirin for the Treatment of Hantavirus Cardiopulmonary Syndrome in North America
2004
Unplanned Extubation: Predictors of Successful Termination of Mechanical Ventilatory Support
1994
Systemic Host Responses in Severe Sepsis Analyzed by Causative Microorganism and Treatment Effects of Drotrecogin Alfa (Activated)
2003
Double-blind randomised controlled trial of monoclonal antibody to human tumour necrosis factor in treatment of septic shock
1998
Initial hormonal and metabolic profile in critically ill patients with community-acquired lobar pneumonia.
1989
Nasogastric and Nasoenteric Feeding Tubes
1998
Drotrecogin Alfa (activated) Improves In-hospital and 90-day Survival in Patients With Severe Sepsis and Community-acquired Pneumoni
2003
Spectrum of Hantavirus Infection: Hemorrhagic Fever with Renal Syndrome and Hantavirus Pulmonary Syndrome
1999
Double-blind randomised controlled trial of monoclonal antibody to human tumour necrosis factor in treatment of septic shock. NORASEPT II Study Group.
1998